Roactemra supply pressure to continue as EMA approves COVID-19 indication

Ongoing Roactemra supply difficulties are set to continue as the European Medicines Agency approves its use for adults with severe COVID-19  who are in receipt of systemic treatment with corticosteroids and requiring supplemental oxygen or mechanical ventilation.

Read more below..

RoActemra (tocilizumab) approved by EMA for use in severe COVID-19